78. 下垂体前葉機能低下症 Hypopituitarism Clinical trials / Disease details


臨床試験数 : 494 薬物数 : 391 - (DrugBank : 49) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 100

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00133354
(ClinicalTrials.gov)
November 200119/8/2005Arimidex Multicenter Trial in Growth Hormone (GH) Deficient BoysDouble-blind Trial Investigating the Safety and Efficacy of the Inhibitor Anastrozole (ARIMIDEX) in Delaying Epiphyseal Fusion and Increasing Height Potential of Adolescent Males With Growth Hormone (GH) DeficiencyHypopituitarismDrug: Arimidex (Anastrozole);Drug: Placebo;Drug: Growth HormoneNemours Children's ClinicAstraZeneca;Genentech, Inc.;EMD SeronoCompleted11 Years18 YearsMale53Phase 2/Phase 3United States
2EUCTR2012-001183-30-Outside-EU/EEA
(EUCTR)
09/03/2012The purpose of this study is to see if Arimidex, an aromatase inhibitor, can delay bone fusion and increase predicted adult height in boys who are growth hormone deficient, in puberty, and who are taking growth hormone.Double-blind trial investigating the safety and efficacy of the inhibitor anastrozole (arimidex) in delaying epiphyseal fusion and increasing height potential of adolescent males with growth hormone (GH) deficiency. hypopituitarism
MedDRA version: 14.1;Level: PT;Classification code 10021067;Term: Hypopituitarism;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: Arimidex
Product Name: Arimidex
Product Code: ZD1033
INN or Proposed INN: anastrozole
Other descriptive name: ANASTROZOLE
Nemours Children's ClinicNULLNAFemale: no
Male: yes
53United States